Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05904691 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
A Phase 1 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Ocugenix Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 3
- Study locations
NCT05904691 is a Phase 1 study of Neovascular Age-related Macular Degeneration (nAMD) that is actively recruiting participants, run by Ocugenix Corporation. The registered enrollment target is 19 participants, below the 206-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05904691, a Phase 1 study of Neovascular Age-related Macular Degeneration (nAMD), is actively recruiting participants, sponsored by Ocugenix Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 3
- Study locations
Study Summary
Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
Conditions Studied
Interventions
- DRUG OCU-10-C-110 for Injection
Study Locations (3)
Texas
- Retina Research Institute of Texas - Abilene
- Strategic Clinical Research Group LLC - Willow Park
Indiana
- Raj K. Maturi, M.D., P.C. - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05904691
The ClinicalTrials.gov registry entry for NCT05904691 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (91% lower). The listed sponsor is Ocugenix Corporation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 1 intervention - of which OCU-10-C-110 for Injection is the first listed.
NCT05904691 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Indiana.
Frequently Asked Questions
What is clinical trial NCT05904691 about?
NCT05904691 is a clinical study titled "Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration". Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
What is the current status of trial NCT05904691?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2023-11-01. Estimated completion is 2026-11-30.
What conditions does trial NCT05904691 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD).
What interventions are being tested in trial NCT05904691?
The interventions under investigation include: OCU-10-C-110 for Injection (DRUG).
Who is sponsoring clinical trial NCT05904691?
This trial is sponsored by Ocugenix Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05904691 being conducted?
This trial has 3 study locations across Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration (nAMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
RECRUITING · Phase 3
-
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 3
-
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 4
-
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.